TG Therapeutics (TGTX) Projected to Announce Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) is anticipated to issue its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to post earnings of $0.3668 per share and revenue of $245.47 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 8:30 AM ET.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The business had revenue of $240.34 million during the quarter, compared to analysts’ expectations of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%. TG Therapeutics’s revenue for the quarter was up 70.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.17 EPS. On average, analysts expect TG Therapeutics to post $0.92 EPS for the current fiscal year and $2.65 EPS for the next fiscal year.

TG Therapeutics Price Performance

Shares of TGTX opened at $61.18 on Friday. TG Therapeutics has a fifty-two week low of $26.76 and a fifty-two week high of $61.76. The firm’s 50-day simple moving average is $55.33 and its two-hundred day simple moving average is $43.75. The stock has a market cap of $9.36 billion, a PE ratio of 22.33, a price-to-earnings-growth ratio of 2.58 and a beta of 1.80. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27.

Wall Street Analyst Weigh In

TGTX has been the topic of a number of analyst reports. Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 6th. Weiss Ratings lowered TG Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. JPMorgan Chase & Co. raised their price objective on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. B. Riley Financial lifted their price objective on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Finally, Bank of America boosted their target price on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $63.00.

Insider Buying and Selling

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the sale, the director directly owned 168,640 shares in the company, valued at approximately $9,268,454.40. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 8.87% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood cancers. The company’s research and development programs are centered on therapies that target B cells and the immune system.

TG Therapeutics’ primary marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of relapsing forms of multiple sclerosis in adults.